← Leaderboards
David M Muschatt
Tulane University Of Louisiana
$847,086
Attributed
$847,086
Total exposure
26
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $257.1K · FY2005–06$500K$375K$250K$125K$0
'05
'06
Funding mix
By agency
NIH$847,086 · 26
By mechanism
M01$847,086 · 26
Top collaborators
No co-investigators on record.
Most similar at Tulane University Of Louisiana
Same institution · by research overlap
- Hua Lu$18,463,532
- Lu Qi$19,868,722
- Gary B Baskin$798,496
- Russell Barrett Van Dyke$24,377,705
- Yiping Chen$15,405,099
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchHiv InfectionsHuman Therapy EvaluationAids TherapyAntiaids AgentOpportunistic InfectionsDrug Screening /EvaluationProtease InhibitorReverse Transcriptase InhibitorsLongitudinal Human StudyHuman Immunodeficiency Virus 1Microorganism Disease ChemotherapyCombination ChemotherapyDrug Adverse EffectAntifungal AgentsChemopreventionBody CompositionMyocardial InfarctionInterleukin 2Angina PectorisHypoglycemic AgentsCholesterolCardiovascular Agents
Grant awards (41)
TRIAL COMPARING TWO STRATEGIES FOR MANAGEMENT OF ANTIRETROVIRAL THERAPY$107,995
M01 · FY2006 · RR · contact PI
STUDY OF LONG-TERM EFFECTIVENESS OF THREE INITIAL HAART STRATEGIES IN HIV PTS$59,639
M01 · FY2006 · RR · contact PI
CPCRA 060: A PROSPECTIVE STUDY OF LONG-TERM CLINICAL, VIROLOGIC OUTCOMES IN HIV$33,849
M01 · FY2006 · RR · contact PI
METABOLIC CONSEQUENCES OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN HIV$32,236
M01 · FY2006 · RR · contact PI
STUDY OF SUBCUTANEOUS RECOMBINANT IL-2 IN PATIENTS WITH HIV-1 INFECTION$16,119
M01 · FY2006 · RR · contact PI
COLLECTION AND USE OF BLOOD FOR GENETIC AND OTHER RELATED ANALYSES$7,253
M01 · FY2006 · RR · contact PI
TRIAL COMPARING TWO STRATEGIES FOR MANAGEMENT OF ANTIRETROVIRAL THERAPY$82,858
M01 · FY2005 · RR
STUDY OF LONG-TERM EFFECTIVENESS OF THREE INITIAL HAART STRATEGIES IN HIV PTS$46,352
M01 · FY2005 · RR
CPCRA 060: A PROSPECTIVE STUDY OF LONG-TERM CLINICAL, VIROLOGIC OUTCOMES IN HIV$32,816
M01 · FY2005 · RR
METABOLIC CONSEQUENCES OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN HIV$22,971
M01 · FY2005 · RR
STUDY OF SUBCUTANEOUS RECOMBINANT IL-2 IN PATIENTS WITH HIV-1 INFECTION$12,306
M01 · FY2005 · RR
A PRESCRIBED 4-MONTH STRUCTURED TREATMENT INTERRUPTION IN HIV-INFECTED PATIENTS$11,485
M01 · FY2005 · RR
Trial Comparing Two Strategies for Management of Therapy$102,527
M01 · FY2004 · RR
Study of Long-Term Effectiveness of Three Initial HAART Strategies in HIV Pts.$93,141
M01 · FY2004 · RR
CPCRA 060: A Prospective Study of Long-Term Clinical$61,372
M01 · FY2004 · RR
Metabolic Consequences of Highly Active Antiretroviral Therapy (HAART) in HIV$45,488
M01 · FY2004 · RR
A Prescribed 4-Month Structured Treatment Interruption$33,213
M01 · FY2004 · RR
Study of Subcutaneous Recombinant IL-2 in Patient w/ HIV$23,106
M01 · FY2004 · RR
IMMUNOLOGIC OUTCOMES IN HIV INFECTED INDIVIDUALS$0
M01 · FY2001 · RR
SAFETY AND EFFICACY OF ADEFOVIR DIPIVOXIL (BIS-POM-PMEA) IN SURVIVAL--HIV$0
M01 · FY2001 · RR
SAFETY &EFFICACY OF NELFINAVIR ADDED TO BACKGROUND ANTIRETROVIRAL NU$0
M01 · FY2001 · RR
CPCRA 059:IMPACT OF 2 DOSES OF SUBCUTANEOUS RECOMBINANT IL 2 ON VIRAL$0
M01 · FY2001 · RR
150 603:TRIAL OF VORICONAZOLE VS AMBISOME FOR ANTIFUNGAL THERAPY IN H$0
M01 · FY2001 · RR
PROPHYLAXIS FOR MAC, PNEUMONIA, AND HIV INFECTION$0
M01 · FY2001 · RR
ANTIRETROVIRAL TREATMENT STRATEGIES FOR HIV INFECTION$0
M01 · FY2001 · RR
VORICONAZOLE VS AMPHOTERICIN B IN ASPERGILLOSIS$0
M01 · FY2001 · RR
HAART STRATEGIES IN HIV INFECTION$0
M01 · FY2001 · RR
VORICONAZOLE IN SUPPRESSION OF CRYPTOCOCCAL MENINGITIS$0
M01 · FY2001 · RR
METABOLIC CONSEQUENCES OF HAART IN HIV INFECTION$0
M01 · FY2001 · RR
150 603:TRIAL OF VORICONAZOLE VS AMBISOME FOR ANTIFUNGAL THERAPY IN H$11,180
M01 · FY2000 · RR
DMP266 020:COMBINATION OF DMP266 &INDINAVIR VS INDINAVIR IN HIV+ PAT$11,180
M01 · FY2000 · RR
VORICONAZOLE IN SUPPRESSION OF CRYPTOCOCCAL MENINGITIS$0
M01 · FY2000 · RR
IMMUNOLOGIC OUTCOMES IN HIV INFECTED INDIVIDUALS$0
M01 · FY2000 · RR
HAART STRATEGIES IN HIV INFECTION$0
M01 · FY2000 · RR
VORICONAZOLE VS AMPHOTERICIN B IN ASPERGILLOSIS$0
M01 · FY2000 · RR
ANTIRETROVIRAL TREATMENT STRATEGIES FOR HIV INFECTION$0
M01 · FY2000 · RR
PROPHYLAXIS FOR MAC, PNEUMONIA, AND HIV INFECTION$0
M01 · FY2000 · RR
CPCRA 059:IMPACT OF 2 DOSES OF SUBCUTANEOUS RECOMBINANT IL 2 ON VIRAL$0
M01 · FY2000 · RR
SAFETY AND EFFICACY OF ADEFOVIR DIPIVOXIL (BIS-POM-PMEA) IN SURVIVAL--HIV$0
M01 · FY2000 · RR
SAFETY &EFFICACY OF NELFINAVIR ADDED TO BACKGROUND ANTIRETROVIRAL NU$0
M01 · FY2000 · RR
METABOLIC CONSEQUENCES OF HAART IN HIV INFECTION$0
M01 · FY2000 · RR